(Q37445609)

20 August 2017

1 reference

title

Chemotherapy for ovarian cancer in the older adult (English)

1 reference

20 August 2017

1 reference

1 reference

Christopher B Steer

1

0 references

publication date

16 April 2009

1 reference

Current Treatment Options in Oncology

20 August 2017

published in

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

3-4

1 reference

20 August 2017

page(s)

159-170

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-009-0093-5

20 August 2017

exact match

0 references

cites work

Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma.

1 reference

12 December 2020

Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer

1 reference

12 December 2020

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

1 reference

12 December 2020

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

12 December 2020

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

12 December 2020

The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study

1 reference

12 December 2020

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

1 reference

12 December 2020

Ovarian cancer in younger vs older women: a population-based analysis

1 reference

12 December 2020

Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma

1 reference

12 December 2020

Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers

1 reference

12 December 2020

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study.

1 reference

12 December 2020

Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome

1 reference

12 December 2020

Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study.

1 reference

12 December 2020

Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients

1 reference

12 December 2020

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

1 reference

12 December 2020

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

12 December 2020

Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies

1 reference

12 December 2020

Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer

1 reference

12 December 2020

Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients

1 reference

12 December 2020

Poorer survival of elderly patients with ovarian cancer: a population-based study

1 reference

12 December 2020

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

1 reference

12 December 2020

The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community

1 reference

12 December 2020

Management of cancer in the elderly.

1 reference

12 December 2020

Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer

1 reference

12 December 2020

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

12 December 2020

The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study

1 reference

12 December 2020

ERCC5 is a novel biomarker of ovarian cancer prognosis

1 reference

12 December 2020

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

12 December 2020

International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

1 reference

12 December 2020

Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer

1 reference

12 December 2020

National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients.

1 reference

12 December 2020

Bevacizumab in older patients and patients with poorer performance status

1 reference

12 December 2020

Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience

1 reference

12 December 2020

Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?

1 reference

12 December 2020

Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?

1 reference

12 December 2020

Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer

1 reference

12 December 2020

Management of ovarian cancer in patients older than 80 years of Age.

1 reference

12 December 2020

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

Letter: Creatinine clearance: bedside estimate.

1 reference

12 December 2020

Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study

1 reference

12 December 2020

Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma

1 reference

12 December 2020

Older female cancer patients: importance, causes, and consequences of undertreatment

1 reference

12 December 2020

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.

1 reference

12 December 2020

Lack of cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer

1 reference

12 December 2020

International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency

1 reference

12 December 2020

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

12 December 2020

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

12 December 2020

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer

1 reference

12 December 2020

Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer

1 reference

12 December 2020

Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)

1 reference

12 December 2020

Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer

1 reference

12 December 2020

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

12 December 2020

Estimation of glomerular filtration rate in cancer patients

1 reference

12 December 2020

Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients.

1 reference

12 December 2020

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

12 December 2020

Clinical cancer research: an embattled species

1 reference

12 December 2020

Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum–taxane chemotherapy

1 reference

12 December 2020

Elderly patients with stage III or IV ovarian cancer: should they receive standard care?

1 reference

12 December 2020

Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study

1 reference

12 December 2020

10.1007/S11864-009-0093-5

Identifiers

DOI

1 reference

20 August 2017

1 reference